Literature DB >> 8586316

Practical application of three polymorphic microsatellites in intron 40 of the human von Willebrand factor gene.

P Casaña1, F Martinez, J A Aznar, J I Lorenzo, J I Jorquera.   

Abstract

Intron 40 of the human von Willebrand factor gene contains a region with variable-number tandem repeats (VNTR), type (ATCT)n, showing length polymorphism. In order to carry out family studies of von Willebrand's disease, we performed PCR procedures to analyze 3 previously described microsatellites from that region, both in normal individuals and in von Willebrand disease patients. Three pairs of primers were used to amplify independently nucleotides 1890-1991 (VNTR 1), 2215-2380 (VNTR 2) and 1640-1794 (VNTR 3) from intron 40. The observed heterozygosities (0.75, 0.73 and 0.86 for VNTRs 1, 2 and 3, respectively) were in good agreement with the expected heterozygosities derived from the allele frequencies (0.70, 0.73 and 0.79, respectively). Furthermore, the combination of the 3 VNTRs showed 96% of heterozygosity, which correspond with the 98% expected value under linkage equilibrium. Therefore, our conclusion is that the use of these 3 markers, especially VNTR 3, constitutes a rapid and reliable method for performing segregation studies in von Willebrand disease families.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586316     DOI: 10.1159/000217171

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  An unexpected transmission of von Willebrand disease type 3: the first case of maternal uniparental disomy 12.

Authors:  Pierre Boisseau; Mathilde Giraud; Catherine Ternisien; Agnès Veyradier; Edith Fressinaud; Armelle Lefrancois; Stéphane Bezieau; Marc Fouassier
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

2.  Haplotype-assisted characterization of germline mutations at short tandem repeat loci.

Authors:  Miriam Müller; Ulla Sibbing; Carsten Hohoff; Bernd Brinkmann
Journal:  Int J Legal Med       Date:  2009-11-11       Impact factor: 2.686

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.